ADC Therapeutics SA

Historical 13F Holders

Symbol
ADCT
CUSIP
H0036K147
All holders as of
Q3 2026
Type
Equity
Class
SHS
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for H0036K147 since 12/18/2024, largest first.

Filer % of Class Filed
Bain Capital Life Sciences Opportunities IV, L.P. 13G 10.0% 10/29/2026
Event 10/22/2026
Nantahala Capital Management, LLC 13G
9.7% 8/14/2026
Event 6/30/2026
TCG Crossover GP II, LLC 13G
9.2% 2/17/2026
Event 10/27/2025
BlackRock, Inc. 13G 5.4% 7/27/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (6)
Redmile Group, LLC 13G/A
9.9%
Checked 5% or less
4/24/2026
Event 4/20/2026
HPWH TH AG 13G/A
9.6%
Checked 5% or less
5/19/2025
Event 5/15/2025
Oaktree Capital Group Holdings GP, LLC 13G/A
4.1% 11/5/2025
Event 9/30/2025
Point72 Asset Management, L.P. 13G/A
4.0% 2/17/2026
Event 12/31/2025
Orbimed Advisors LLC 13G/A
2.6% 2/17/2026
Event 12/31/2025
Prosight Management, LP 13G/A
0.3% 11/13/2026
Event 9/30/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 110 82.0 M $100M
2026 Q2 113 80.7 M $86.7M
2026 Q1 118 83.5 M $313M
2025 Q4 115 82.9 M $293M
2025 Q3 107 67.8 M $271M
2025 Q2 88 68.0 M $182M
2025 Q1 84 54.8 M $77.3M
2024 Q4 85 56.5 M $112M
2024 Q3 80 54.9 M $173M
2024 Q2 75 51.8 M $164M
2024 Q1 39 34.7 M $156M
2023 Q4 39 34.0 M $56.4M
2023 Q3 42 39.5 M $35.4M
2023 Q2 57 45.4 M $97.5M
2023 Q1 61 46.6 M $90.9M
2022 Q4 63 38.8 M $149M
2022 Q3 68 36.6 M $177M
2022 Q2 61 34.5 M $274M
2022 Q1 53 34.1 M $501M
2021 Q4 58 33.8 M $683M
2021 Q3 57 32.8 M $891M
2021 Q2 61 33.5 M $816M
2021 Q1 61 32.8 M $801M
2020 Q4 52 31.6 M $1.01B
2020 Q3 54 28.2 M $922M
2020 Q2 42 21.6 M $1.00B